JP2019512465A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019512465A5 JP2019512465A5 JP2018544186A JP2018544186A JP2019512465A5 JP 2019512465 A5 JP2019512465 A5 JP 2019512465A5 JP 2018544186 A JP2018544186 A JP 2018544186A JP 2018544186 A JP2018544186 A JP 2018544186A JP 2019512465 A5 JP2019512465 A5 JP 2019512465A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- alkyl
- substituted
- compound according
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662297450P | 2016-02-19 | 2016-02-19 | |
| US62/297,450 | 2016-02-19 | ||
| PCT/US2017/018511 WO2017143291A1 (en) | 2016-02-19 | 2017-02-17 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019512465A JP2019512465A (ja) | 2019-05-16 |
| JP2019512465A5 true JP2019512465A5 (https=) | 2020-03-26 |
| JP6956098B2 JP6956098B2 (ja) | 2021-10-27 |
Family
ID=59625486
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018544186A Active JP6956098B2 (ja) | 2016-02-19 | 2017-02-17 | 変異体ｐ５３機能を復元させるための方法および化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US10138219B2 (https=) |
| EP (1) | EP3416638A4 (https=) |
| JP (1) | JP6956098B2 (https=) |
| KR (1) | KR102868217B1 (https=) |
| CN (2) | CN109069481A (https=) |
| AU (1) | AU2017221472B2 (https=) |
| CA (1) | CA3010847C (https=) |
| IL (2) | IL286839B (https=) |
| MX (1) | MX383904B (https=) |
| WO (1) | WO2017143291A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102868217B1 (ko) | 2016-02-19 | 2025-10-14 | 피엠브이 파마슈티컬스 인코포레이티드 | 돌연변이 p53 기능을 회복시키는 방법 및 화합물 |
| DK4034104T3 (da) * | 2019-09-23 | 2025-10-06 | Pmv Pharmaceuticals Inc | Metoder og forbindelser til genoprettelse af mutant p53-funktion |
| WO2021231474A1 (en) * | 2020-05-12 | 2021-11-18 | Pmv Pharmaceuticals, Inc. | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION |
| CN111686127B (zh) * | 2020-06-04 | 2022-02-15 | 华南理工大学 | 锌铁纳米材料在降解突变p53蛋白中的应用 |
| CN113750246B (zh) * | 2020-06-04 | 2023-12-05 | 华南理工大学 | ZIF-8纳米材料在降解广谱突变p53蛋白中的应用 |
| WO2021262684A1 (en) * | 2020-06-22 | 2021-12-30 | Pmv Pharmaceuticals, Inc. | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION |
| US11926632B2 (en) * | 2020-06-22 | 2024-03-12 | Pmv Pharmaceuticals, Inc. | Methods and compounds for restoring mutant p53 function |
| US12570645B2 (en) * | 2020-06-22 | 2026-03-10 | Pmv Pharmaceuticals, Inc. | Uses of p53 x-ray co-crystal structures |
| CA3183025A1 (en) * | 2020-06-24 | 2021-12-30 | Melissa Dumble | Companion diagnostic tool for mutant p53 reactivating compounds |
| US20230049952A1 (en) * | 2020-06-24 | 2023-02-16 | Pmv Pharmaceuticals, Inc. | Methods and compounds for restoring mutant p53 function |
| WO2021262484A1 (en) * | 2020-06-24 | 2021-12-30 | Pmv Pharmaceuticals, Inc. | Combination therapy for treatment of cancer |
| EP4267553A1 (en) * | 2020-12-24 | 2023-11-01 | Escient Pharmaceuticals, Inc. | Modulators of mas-related g-protein receptor x2 and related products and methods |
| WO2022213975A1 (en) * | 2021-04-08 | 2022-10-13 | Jacobio Pharmaceuticals Co., Ltd. | Compounds targeting y220c mutant of p53 |
| UY39890A (es) * | 2021-08-10 | 2023-03-31 | Jacobio Pharmaceuticals Co Ltd | Compuestos con diana en mutante de p53 |
| WO2023025324A1 (zh) * | 2021-08-27 | 2023-03-02 | 杭州紫晶医药科技有限公司 | 作为p53调节剂的化合物 |
| AU2023213949A1 (en) | 2022-01-27 | 2024-07-25 | Pmv Pharmaceuticals, Inc. | Deuterated compounds for restoring mutant p53 function |
| WO2024017384A1 (zh) * | 2022-07-22 | 2024-01-25 | 深圳众格生物科技有限公司 | 恢复p53突变功能的化合物及其应用 |
| CN119968361A (zh) * | 2022-08-22 | 2025-05-09 | 北京加科思新药研发有限公司 | 靶向p53 Y220突变体的化合物 |
| CN120077047A (zh) * | 2022-10-21 | 2025-05-30 | 正大天晴药业集团股份有限公司 | 大环类化合物及其医药用途 |
| TW202435861A (zh) * | 2022-12-08 | 2024-09-16 | 大陸商北京加科思新藥研發有限公司 | 靶向p53突變體的化合物 |
| CN121693500A (zh) * | 2023-08-09 | 2026-03-17 | 德睿智药(苏州)新药研发有限公司 | 用于调节p53功能的新型杂环类化合物 |
| WO2025011684A2 (zh) * | 2023-10-20 | 2025-01-16 | 上海宇道生物技术有限公司 | 一类n-磺酰酰胺含氮稠杂环类化合物及其应用 |
| WO2025242903A1 (en) * | 2024-05-24 | 2025-11-27 | Onco3R Therapeutics Bv | Compounds and pharmaceutical compositions thereof for the treatment of proliferative diseases |
| WO2026025042A1 (en) | 2024-07-26 | 2026-01-29 | Dana-Farber Cancer Institute, Inc. | P53 targeting compounds and uses thereof |
| WO2026067649A1 (zh) * | 2024-09-27 | 2026-04-02 | 奇树医药公司 | 恢复p53突变功能的化合物及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1329493A (zh) | 1998-12-02 | 2002-01-02 | 辉瑞产品公司 | 恢复p53家族蛋白质的构象稳定性的方法和组合物 |
| US6770652B2 (en) * | 2001-10-18 | 2004-08-03 | Duquesne University Of The Holy Ghost | Multiple acting anti-angiogenic and cytotoxic compounds and methods for using the same |
| WO2005051908A1 (en) * | 2003-11-25 | 2005-06-09 | Novo Nordisk A/S | Indole derivatives for use as chemical uncoupler |
| JP2008505910A (ja) | 2004-07-08 | 2008-02-28 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | Ｐｋｃ−シータのインヒビターとして有用なピリミジン誘導体 |
| WO2006136823A1 (en) | 2005-06-21 | 2006-12-28 | Astex Therapeutics Limited | Heterocyclic containing amines as kinase b inhibitors |
| US8822420B2 (en) * | 2008-03-13 | 2014-09-02 | Universita Degli Studi Di Trieste | Peptides and aptamers thereof as specific modulators of mutant p53 function |
| HUE025471T2 (hu) * | 2008-04-16 | 2016-03-29 | Karobio Ab | Új ösztrogén receptor ligandumok |
| GB0808282D0 (en) * | 2008-05-07 | 2008-06-11 | Medical Res Council | Compounds for use in stabilizing p53 mutants |
| DK2410844T3 (en) * | 2009-03-27 | 2016-07-04 | Merck Sharp & Dohme | Inhibitors of hepatitis C virus replication |
| DE102010049877A1 (de) | 2010-11-01 | 2012-05-03 | Merck Patent Gmbh | 7-((1,2,3)Triazol-4-yl)-pyrrolo(2,3) pyrazinderivate |
| RU2598842C2 (ru) | 2011-01-20 | 2016-09-27 | Мерк Шарп Энд Домэ Корп. | Антагонисты рецептора минералокортикоидов |
| GB201110390D0 (en) | 2011-06-20 | 2011-08-03 | Medical Res Council | Compounds for use in stabilising p53 mutants |
| US9517252B2 (en) * | 2011-09-09 | 2016-12-13 | Agency For Science, Technology And Research | p53 activating peptides |
| EP2809656A2 (en) | 2011-12-28 | 2014-12-10 | Allergan, Inc. | Benzimidazole derivatives as selective blockers of persistent sodium current |
| US8822689B2 (en) | 2012-09-19 | 2014-09-02 | Merial Limited | Aryloazol-2-yl cyanoethylamino compounds, method of making and method of using thereof |
| EP3145512B1 (en) * | 2014-05-19 | 2019-07-17 | Jiangsu Hengrui Medicine Co., Ltd. | Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors |
| WO2016004513A1 (en) * | 2014-07-11 | 2016-01-14 | Simon Fraser University | Anti-bacterial pyruvate kinase modulator compounds, compositions, uses and methods |
| CN104672241B (zh) * | 2015-01-29 | 2018-04-24 | 王磊 | 吡咯并[2,3-d]嘧啶类化合物及其用途 |
| KR102868217B1 (ko) | 2016-02-19 | 2025-10-14 | 피엠브이 파마슈티컬스 인코포레이티드 | 돌연변이 p53 기능을 회복시키는 방법 및 화합물 |
-
2017
- 2017-02-17 KR KR1020187026965A patent/KR102868217B1/ko active Active
- 2017-02-17 CN CN201780013450.6A patent/CN109069481A/zh active Pending
- 2017-02-17 IL IL286839A patent/IL286839B/en unknown
- 2017-02-17 AU AU2017221472A patent/AU2017221472B2/en active Active
- 2017-02-17 MX MX2018009947A patent/MX383904B/es unknown
- 2017-02-17 US US15/436,333 patent/US10138219B2/en active Active
- 2017-02-17 WO PCT/US2017/018511 patent/WO2017143291A1/en not_active Ceased
- 2017-02-17 JP JP2018544186A patent/JP6956098B2/ja active Active
- 2017-02-17 CA CA3010847A patent/CA3010847C/en active Active
- 2017-02-17 EP EP17753995.4A patent/EP3416638A4/en not_active Withdrawn
- 2017-02-17 CN CN202411302298.1A patent/CN119161324B/zh active Active
-
2018
- 2018-08-15 IL IL261175A patent/IL261175B/en unknown
- 2018-10-18 US US16/163,829 patent/US10640485B2/en active Active
-
2020
- 2020-03-16 US US16/819,934 patent/US11339141B2/en active Active
-
2022
- 2022-02-24 US US17/679,568 patent/US20220213062A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019512465A5 (https=) | ||
| JP2009530424A5 (https=) | ||
| JP2020536106A (ja) | Ｈｉｖの処置に有用なインターフェロン遺伝子の刺激物質（ｓｔｉｎｇ）の調節物質 | |
| Ranjan et al. | Recognition of HIV-TAR RNA using neomycin–benzimidazole conjugates | |
| Cortez et al. | Incorporation of phosphonate into benzonaphthyridine toll-like receptor 7 agonists for adsorption to aluminum hydroxide | |
| JP2007529421A5 (https=) | ||
| Huang et al. | Platinum (II) complexes containing aminophosphonate esters: Synthesis, characterization, cytotoxicity and action mechanism | |
| Xu et al. | Protective effect of intestinal trefoil factor on injury of intestinal epithelial tight junction induced by platelet activating factor | |
| US20200339993A1 (en) | Aptamer Conjugates with N-Heterocyclic Carbene Metal Complexes for Targeted Drug Delivery | |
| US7872027B2 (en) | Low molecular weight Myc-max inhibitors | |
| JP2013518036A5 (https=) | ||
| AU2014235957A1 (en) | Fluorescent-HAP: a diagnostic stain for HBV cores in cells | |
| JP2024522183A (ja) | 非標準ｇ四重鎖構造に結合する化合物ならびにそれを作製および使用する方法 | |
| Booijink et al. | A type IV Autotaxin inhibitor ameliorates acute liver injury and nonalcoholic steatohepatitis | |
| JP2012505905A5 (https=) | ||
| CN108853106B (zh) | 亚胺吩嗪类化合物作为狂犬病病毒抑制剂的用途 | |
| CN115916343B (zh) | 卤代呫吨在肿瘤学和病毒学中的新用途 | |
| ES2907624T3 (es) | Inhibidores de oxadiazol de HIPK2 para el tratamiento de la fibrosis renal | |
| WO2016172191A1 (en) | Compounds, compositions and methods for inhibiting cnksr1 | |
| US12544421B2 (en) | VDAC inhibitors for treating inflammatory bowel diseases | |
| CN107540624B (zh) | 热休克蛋白抑制剂及其制备方法和应用 | |
| CA2531869A1 (en) | Compounds having a fused, bicyclic moiety for binding to the minor groove of dsdna | |
| KR20220035275A (ko) | 다발성 골수종 치료 | |
| EP4132657A1 (en) | Compositions and methods for treatment of anticancer-drug resistant cancers | |
| CN114907337B (zh) | 靶向cdk4或cdk6的共价抑制剂及其应用 |